AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2019
Apr 16, 2019
32254_dirs_2019-04-16_a63b4b2b-a279-42be-8082-4aca62972416.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2019-04-12
Reporting Person: Duker Jay S. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-04-12 | Common Stock | M | 20000.00 | $1.77 | Acquired | 37500.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-04-12 | Stock Option (Right to Buy) | $1.77 | M | 20000.00 | Disposed | 2027-06-27 | Common Stock (20000.00) | Direct |
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7